169105-01-5

Basic information

• Product Name: R-(-)-6-hydroxy-1-aminoindan
• Synonyms: R-(-)-6-hydroxy-1-aminoindan;(R)-3-AMino-5-hydroxyindane;(R)-3-amino-2,3-dihydro-1H-inden-5-ol;(1R)-6-Hydroxy-2,3-dihydro-1H-inden-1-amine
• CAS NO: 169105-01-5
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 149.19
• Mol File: 169105-01-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 292.3 °C at 760 mmHg
• Flash Point: 130.6 °C
• Appearance: /
• Density: 1.198 g/cm³
• Refractive Index: 1.622
• CAS DataBase Reference: R-(-)-6-hydroxy-1-aminoindan(CAS DataBase Reference)
• NIST Chemistry Reference: R-(-)-6-hydroxy-1-aminoindan(169105-01-5)
• EPA Substance Registry System: R-(-)-6-hydroxy-1-aminoindan(169105-01-5)

Safety Data

• Hazardous Substances Data: 169105-01-5(Hazardous Substances Data)

Usage

Description

R-(-)-6-hydroxy-1-aminoindan is a hydroxy derivative of Aminoindane (A611715), which is a metabolite of Rasagiline (R126000). Rasagiline is a selective irreversible monoamine oxidase-B (MAO-B) inhibitor, and R-(-)-6-hydroxy-1-aminoindan is associated with its antiparkinsonian properties.

Uses

Used in Pharmaceutical Industry:
R-(-)-6-hydroxy-1-aminoindan is used as an active pharmaceutical ingredient for the development of antiparkinsonian agents. It contributes to the treatment of Parkinson's disease by inhibiting the activity of MAO-B, an enzyme responsible for the breakdown of dopamine in the brain, thereby increasing dopamine levels and alleviating the symptoms of the disease.
Used in Research and Development:
R-(-)-6-hydroxy-1-aminoindan is also used as a research compound in the field of neuroscience and pharmacology. It serves as a valuable tool for studying the mechanisms of action of MAO-B inhibitors and their potential applications in the treatment of neurodegenerative disorders, such as Parkinson's disease.

InChI:InChI=1/C9H11NO/c10-9-4-2-6-1-3-7(11)5-8(6)9/h1,3,5,9,11H,2,4,10H2/t9-/m1/s1

Upstream product

• 209394-88-7 6-chloroacetoxy-N-trifluoroacetyl-(R)-1-aminoindan 
• 10277-74-4 (R)-1-Aminoindane 
• 155666-94-7 N-trifluoroacetyl-(R)-1-aminoindan 
• 209394-87-6 6-chloroacetyl-N-trifluoroacetyl-(R)-1-aminoindan 

Downstream Products

• 947674-87-5 N-[(R)-6-hydroxyindan-1-yl]carbamic acid tert-butyl ester 
• 209394-27-4 ladostigil 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Aminoindan derivatives

This invention is directed to compounds of the following formula wherein when a is O, b is 1 or 2; when a is 1, b is 1, m is from 0-3 X is O or S, Y is halogeno, R1is hydrogen C1-4alkyl, R2is hydrogen, C1-4alkyl, or optionally substituted propargyl and R3and R4are each independently hydrogen, C1-8alkyl, C6-12aryl, C6-12aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADC), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.